Evaluate the Safety and Pharmacokinetics of Ricolinostat

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 12, 2022

Primary Completion Date

January 30, 2022

Study Completion Date

January 6, 2023

Conditions
Peripheral Nervous System Diseases
Interventions
DRUG

ricolinostat

"This study is an open-label, single-dose phase I clinical study to evaluate the safety and pharmacokinetics of ricolinostat in healthy Chinese adult subjects.~12 subjects are planned to be enrolled, both male and female, and all will receive the investigational drug.~This study includes the screening period, baseline period, dosing/observation period, discharge and follow-up period."

Trial Locations (1)

Unknown

Bethune First Hospital Of Jilin University, Changchun

All Listed Sponsors
lead

Beijing 3E-Regenacy Pharmaceuticals Co., Ltd.

INDUSTRY